The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 350:619 February 5, 2004 Number 6
NextNext

Fondaparinux in Pulmonary Embolism

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by The Matisse Investigators
-PubMed Citation
To the Editor: The Matisse Investigators (Oct. 30 issue)1 conclude that fondaparinux is as effective as intravenous unfractionated heparin in the treatment of hemodynamically stable pulmonary embolism. The authors state that "care was taken to apply the highest treatment standards to the use of unfractionated heparin." Heparin infusions were adjusted to maintain the activated partial-thromboplastin time at a value that was 1.5 to 2.5 times the control value. Modern thromboplastin reagents are more sensitive than the older reagents that were used to determine this traditional therapeutic range. Suboptimal dosing will occur if this activated partial-thromboplastin time ratio is used as . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.